2026-04-17T16:59:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/129902025-10-24T10:17:32Zcom_2072_378070com_2072_378040col_2072_378092

SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024) Arregui, Marta Carrasco, Irene Serrano, Cesar HINDI, NADIA Martinez-Trufero, Javier Martinez-Garcia, Jeronimo Sarcoma Tumors de parts toves - Tractament Tumors de parts toves - Diagnòstic DISEASES::Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms Other subheadings::Other subheadings::/therapy DISEASES::Neoplasms::Neoplasms by Site::Soft Tissue Neoplasms Other subheadings::Other subheadings::/diagnosis DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Sarcoma ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de los tejidos blandos Otros calificadores::Otros calificadores::/terapia ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de los tejidos blandos Otros calificadores::Otros calificadores::/diagnóstico ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::sarcoma Rare cancer; Sarcoma; Soft-tissue sarcoma Cáncer raro; Sarcoma; Sarcoma de tejidos blandos Càncer rar; Sarcoma; Sarcoma de teixits tous Soft-tissue sarcomas are rare, diverse malignant tumors of mesenchymal origin, requiring diagnosis and treatment by a specialized multidisciplinary team. Initial assessment includes radiology and biopsy, followed by wide surgical resection with clear margins for localized cases. Radiotherapy is recommended for large, deep, high-grade tumors or after incomplete resection, while perioperative chemotherapy may be considered for high-risk cases. In oligometastatic disease, combining local and systemic therapies is an option. Anthracycline-based chemotherapy is the first-line treatment in advanced disease, though other drugs show efficacy in certain subtypes. Given the limited options, enrolling in clinical trials is advised for patients needing further treatment. 2025-10-24T10:17:32Z 2025-10-24T10:17:32Z 2025-10-24T10:17:32Z 2025-04-25T09:46:42Z 2025-04-25T09:46:42Z 2025-04 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/12990 Clinical and Translational Oncology;27 https://doi.org/10.1007/s12094-024-03842-5 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Scientia